Clinical Trial Update: A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial update for HMBD-501 evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in HER3-expressing solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• HMBD-501

Snippet

Sponsor: Hummingbird Bioscience | Conditions: Melanoma (Skin), Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING